What Kainova Therapeutics’ latest financing reveals about the future of CCR8-targeted cancer therapies

Find out how Kainova Therapeutics’ $32M CAD funding could reshape GPCR-based immuno-oncology and inflammation drug development.

Find out how Kainova Therapeutics’ $32M CAD funding could reshape GPCR-based immuno-oncology and inflammation drug development.